Downregulation of lncRNA
FOXM1
long non‑coding RNA
malignant mesothelioma
plasmacytoma variant translocation 1
small interfering RNA
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
13
08
2021
accepted:
12
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
11
1
2022
Statut:
ppublish
Résumé
Malignant mesothelioma is a highly aggressive tumor, and an effective strategy for its treatment is not yet available. Long non‑coding RNAs (lncRNAs) have been reported to be associated with various biological processes, including the regulation of gene expression of cancer‑related pathways. Among various lncRNAs, plasmacytoma variant translocation 1 (
Identifiants
pubmed: 34859258
doi: 10.3892/or.2021.8238
pii: 27
pmc: PMC8674703
doi:
pii:
Substances chimiques
FOXM1 protein, human
0
Forkhead Box Protein M1
0
PVT1 long-non-coding RNA, human
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Cancer. 2017 Jul 25;17(8):475-488
pubmed: 28740119
Biotechniques. 2007 Jan;42(1):71-5
pubmed: 17269487
Nat Rev Genet. 2009 Mar;10(3):155-9
pubmed: 19188922
PLoS One. 2013 Aug 19;8(8):e70940
pubmed: 23976967
J Cancer. 2021 Jan 1;12(2):611-621
pubmed: 33391456
Recent Pat Anticancer Drug Discov. 2017;12(3):247-259
pubmed: 28440206
Oncol Lett. 2016 Oct;12(4):2445-2450
pubmed: 27698811
Lung Cancer. 2014 Feb;83(2):240-5
pubmed: 24360321
Biotechniques. 2009 Apr;46(4):265-74
pubmed: 19450233
Med Sci Monit. 2018 Dec 01;24:8685-8692
pubmed: 30504754
J Thorac Oncol. 2014 Jul;9(7):998-1007
pubmed: 24926545
Mol Med Rep. 2016 Mar;13(3):2696-700
pubmed: 26861549
J Exp Clin Cancer Res. 2017 May 8;36(1):63
pubmed: 28482906
Biochem Biophys Res Commun. 2016 Feb 26;471(1):10-4
pubmed: 26850852
Oncol Rep. 2014 Jun;31(6):2660-8
pubmed: 24715097
Am J Ind Med. 2006 Jan;49(1):1-7
pubmed: 16362942
Cancer Cell Int. 2018 Jul 11;18:98
pubmed: 30008615
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
PLoS Genet. 2009 Apr;5(4):e1000459
pubmed: 19390609
Oncol Lett. 2017 Dec;14(6):6553-6561
pubmed: 29163688
Clin Cancer Res. 2017 Apr 15;23(8):2071-2080
pubmed: 27756785
Am J Surg Pathol. 2017 Aug;41(8):1045-1052
pubmed: 28394802
Br J Cancer. 2013 Oct 1;109(7):1965-73
pubmed: 23989951
Int J Occup Med Environ Health. 2004;17(1):179-85
pubmed: 15212222
Biomed Pharmacother. 2018 Oct;106:61-67
pubmed: 29957467
Clin Cancer Res. 2007 Oct 1;13(19):5745-55
pubmed: 17908964
Mol Genet Genomics. 2018 Feb;293(1):1-15
pubmed: 28894972
Cell. 2009 Feb 20;136(4):629-41
pubmed: 19239885
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Hum Mol Genet. 2010 Oct 15;19(R2):R152-61
pubmed: 20729297
Epigenomics. 2018 Jun;10(6):723-732
pubmed: 29693417
BMC Biol. 2010 Dec 21;8:149
pubmed: 21176148
Bull World Health Organ. 2011 Oct 1;89(10):716-24, 724A-724C
pubmed: 22084509
Oncol Lett. 2017 Sep;14(3):3809-3816
pubmed: 28927151
Nature. 2009 Mar 12;458(7235):223-7
pubmed: 19182780
Int J Cancer. 2009 Jan 1;124(1):201-7
pubmed: 18792097
Bioessays. 2010 Jul;32(7):599-608
pubmed: 20544733
Curr Opin Cell Biol. 2009 Jun;21(3):416-25
pubmed: 19447594
PLoS One. 2011;6(10):e25915
pubmed: 21991387
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118
pubmed: 33353982
Cells. 2019 Sep 01;8(9):
pubmed: 31480503
Biosci Rep. 2017 Dec 15;37(6):
pubmed: 29046366
Mol Ther Nucleic Acids. 2019 Jun 7;16:130-140
pubmed: 30861415
Mol Cancer. 2011 Apr 13;10:38
pubmed: 21489289